WEE1 and cancer: Both phase I and phase II clinical trials have suggested that AZD1775, a Wee‐1 inhibitor, as monotherapy or in combination with chemotherapy has high efficacy in treating different cancers, with a well‐tolerated cytotoxic profile.27, 28